Clinical trial NCT00073385: Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Official title: A Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients With Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Lung cancer, Docetaxel, Histone deacetylase inhibitor
Lead sponsor: Titan Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2003-11-21
Enrollment: 225
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized study will assess the efficacy and safety of the combination of Pivanex and docetaxel compared to docetaxel alone in patients with a type of lung cancer called non-small cell lung cancer. Pivanex is an investigational agent, and docetaxel is an approved drug.

Detailed description: Rationale: Pivanex is a histone deacetylase inhibitor that induces tumor differentiation and/or apoptosis. Pivanex has been well tolerated in clinical trials and has shown preliminary evidence of efficacy in patients with non-small cell lung cancer. Docetaxel is an approved drug for second-line treatment of non-small cell lung cancer. Preclinical studies indicate that the combination of Pivanex and docetaxel is synergistic.

Purpose: This open-label randomized trial will evaluate whether combination therapy with Pivanex and docetaxel provides clinical benefit over docetaxel alone in patients with chemotherapy resistant non-small cell lung cancer.

Objectives:

* Compare the survival of patients with non-small cell lung cancer treated with combination therapy with Pivanex and docetaxel vs. docetaxel alone
* Compare the time to disease progression, tumor responses, and safety profile of patients with non-small cell lung cancer treated with combination therapy with Pivanex and docetaxel vs. docetaxel alone

Outline: This is a randomized, open-label, multicenter study in patients with non-small cell lung cancer who have previously been treated with no more than one prior platinum containing chemotherapy regimen. Patients are stratified by ECOG performance status (0-1 vs. 2), response to prior platinum based chemotherapy (progression vs. CR/PR/SD) and prior taxane therapy (yes vs. no). Patients are randomized to 1 of 2 treatment arms.

* Arm A: Patients receive the combination of Pivanex intravenously on Days 1-3 and docetaxel intravenously on Day 4. Treatment repeats every 21 days until disease progression or treatment withdrawal.
* Arm B: Patients receive docetaxel intravenously on Day 1. Treatment repeats every 21 days until disease progression or treatment withdrawal.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Treatment with one prior platinum-based chemotherapy regimen (Eligible patients may include:

  1. Patients previously treated with adjuvant or neoadjuvant chemotherapy (must be completed within 6 months prior to randomization) or
  2. Patients who have received chemotherapy for advanced or metastatic lung cancer);
* Recurrent or progressive NSCLC (local, distant, or both) following initial chemotherapy);
* Measurable or non-measurable disease;
* Males and females, age =\> 18 years;
* Adequate renal function with creatinine =\> 1.5 mg/dl;
* Adequate liver function with alkaline phosphatase =\> 2.5 X upper limit of normal, SGOT, and SGPT =\> 1.5 X upper limit of normal; and total bilirubin =\> upper limit of normal;
* Adequate bone marrow function: platelets \> 100,000/mm3, hemoglobin =\> 9 g/dL, and absolute neutrophil count (ANC) =\> 1,500 cells/mm3;
* Able to give informed consent;
* Discontinuation of previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity;
* A predicted life expectancy of at least 12 weeks; and
* ECOG performance status of 0, 1, or 2.

Exclusion Criteria:

* Receipt of more than one chemotherapy regimen for NSCLC;
* A second malignancy within the last 5 years other than curatively treated carcinoma-in-situ or non-melanoma skin cancer;
* Pregnant or lactating females (Females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control);
* Known HIV-positive patients;
* Acute medical problems, such as ischemic heart or lung disease or uncontrolled systemic infection;
* Patients with any underlying medical conditions or circumstance, which would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints;
* Patients receiving investigational agents within 30 days of the screening visit;
* Known allergy to reagents in the study;
* Prior docetaxel therapy;
* Symptomatic or untreated brain metastases (Patients with brain metastases are eligible if they are clinically and neurologically stable for \> 4 weeks since therapy (radiation therapy, radiosurgery/gamma knife; surgical resection) as determined by the investigator and either off corticosteroids or on a stable dose of corticosteroids).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: La Verne
country: United States
facility: Wilshire Oncology Medical Group
state: California
city: New Orleans
country: United States
facility: Hematology and Oncology Specialists, LLC
state: Louisiana
city: Bronx
country: United States
facility: Montefiore Medical Center, Department of Oncology
state: New York
city: Brooklyn
country: United States
facility: HemOnCare
state: New York
city: Gastonia
country: United States
facility: Gaston Hematology & Oncology Associates
state: North Carolina
city: New Delhi
country: India
facility: Rajiv Gandhi Cancer Institute & Research Center
city: Thiruvananthapuram
country: India
facility: Regional Cancer Centre
city: Edinburgh
country: United Kingdom
facility: University of Edinburgh, Edinburgh Cancer Centre
Study officials:
References: